These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32190952)

  • 1. Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study.
    Sgalla G; Lo Greco E; Calvello M; Varone F; Iovene B; Cerri S; Donatelli P; Vancheri A; Pavone M; Luppi F; Vancheri C; Richeldi L
    Respirology; 2020 Nov; 25(11):1144-1151. PubMed ID: 32190952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis.
    LaCamera PP; Limb SL; Haselkorn T; Morgenthien EA; Stauffer JL; Wencel ML
    Chron Respir Dis; 2019; 16():1479973119879678. PubMed ID: 31558049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Belhassen M; Dalon F; Nolin M; Van Ganse E
    Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
    Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
    Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
    Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
    BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and treatment standards in idiopathic pulmonary fibrosis in the era of antifibrotic drugs in Poland: A real-world practice survey.
    Majewski S; Lewandowska K; Martusewicz-Boros MM; Piotrowski WJ
    Adv Respir Med; 2019; 87(6):221-230. PubMed ID: 31970724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis.
    Aiello M; Bertorelli G; Bocchino M; Chetta A; Fiore-Donati A; Fois A; Marinari S; Oggionni T; Polla B; Rosi E; Stanziola A; Varone F; Sanduzzi A
    Pulm Pharmacol Ther; 2017 Jun; 44():7-15. PubMed ID: 28257817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic pulmonary fibrosis: Significance of the usual interstitial pneumonia (UIP) CT-scan patterns defined in new international guidelines.
    Diridollou T; Sohier L; Rousseau C; Angibaud A; Chauvin P; Gaignon T; Tas M; Lemerre J; Kerjouan M; Salé A; Lederlin M; Jouneau S
    Respir Med Res; 2020 Mar; 77():72-78. PubMed ID: 32416587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.
    Walsh SLF; Lederer DJ; Ryerson CJ; Kolb M; Maher TM; Nusser R; Poletti V; Richeldi L; Vancheri C; Wilsher ML; Antoniou KM; Behr J; Bendstrup E; Brown KK; Corte TJ; Cottin V; Crestani B; Flaherty KR; Glaspole IN; Grutters J; Inoue Y; Kondoh Y; Kreuter M; Johannson KA; Ley B; Martinez FJ; Molina-Molina M; Morais A; Nunes H; Raghu G; Selman M; Spagnolo P; Taniguchi H; Tomassetti S; Valeyre D; Wijsenbeek M; Wuyts WA; Wells AU
    Am J Respir Crit Care Med; 2019 Nov; 200(9):1146-1153. PubMed ID: 31241357
    [No Abstract]   [Full Text] [Related]  

  • 14. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
    Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
    Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
    Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust.
    Casillo V; Cerri S; Ciervo A; Stendardo M; Manzoli L; Flacco ME; Manno M; Bocchino M; Luppi F; Boschetto P
    BMC Pulm Med; 2019 Sep; 19(1):170. PubMed ID: 31488107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.
    Glassberg MK
    Am J Manag Care; 2019 Jul; 25(11 Suppl):S195-S203. PubMed ID: 31419091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.